CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 3.68: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.77%Below 5Y avg (0.93%)
Annual Rate
CNY 0.10Paid annual
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Jul 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.41BCNY358.41M · vs all stocks (USD)
Trailing P/E
46.21xRevenue (TTM)
830.53MCNY123.51M · vs all stocks (USD)
Profit Margin
6.46%Beta
0.2960xvs all stocks
52-Week Change
-29.48%vs all stocks
Market Capitalization
2.41BCNY358.41M · vs all stocks (USD)
Enterprise Value
2.24BCNY332.93M · vs all stocks (USD)
Trailing P/E
46.21xPrice to Sales (TTM)
3.05xPrice to Book (MRQ)
1.57xEnterprise to Revenue
2.70xEnterprise to EBITDA
16.81xGross Margin
27.60%Profit Margin
6.46%Operating Margin
10.81%Return on Assets (TTM)
1.79%Return on Equity (TTM)
4.16%Revenue (TTM)
830.53MCNY123.51M · vs all stocks (USD)
Revenue per Share (TTM)
4.54CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-6.90%Gross Profit (TTM)
203.14MCNY30.21M · vs all stocks (USD)
EBITDA (TTM)
87.58MCNY13.02M · vs all stocks (USD)
Net Income (TTM)
53.62MCNY7.97M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-39.30%Operating Cash Flow (TTM)
156.78MCNY23.32M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
2.65MCNY394.70K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.77%vs all stocks
5-Year Average Dividend Yield
0.93%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
30.25MCNYFY2025 · Dec 31, 2025Revenue
844.54MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
623.66MCNYFY2025 · Dec 31, 2025Gross Profit
220.87MCNYFY2025 · Dec 31, 2025Operating Income
84.49MCNY12.57M · vs all stocks (USD)
Pre-tax Income
80.13MCNYFY2025 · Dec 31, 2025Income Tax Expense
10.86MCNYFY2025 · Dec 31, 2025Net Income
69.26MCNYFY2025 · Dec 31, 2025EBIT
81.04MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
169.66MCNYFY2025 · Dec 31, 2025Research & Development
53.67MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
21.23MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.09MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
8.46MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
908.93KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3500CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
177.59MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
177.59MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
69.26MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-7.11MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
42.66MCNYFY2025 · Dec 31, 2025Free Cash Flow
-101.89MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
402.77MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
69.26MCNYFY2025 · Dec 31, 2025Other Non-cash Items
7.35MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-24.85MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.11MCNYFY2025 · Dec 31, 2025Capital Expenditures
-144.55MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.55BCNYFY2025 · Dec 31, 2025Sale of Investments
1.37BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-317.21MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
141.50MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-79.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-7.81MCNYFY2025 · Dec 31, 2025Other Financing Charges
264.38MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
319.07MCNYFY2025 · Dec 31, 2025Shares Outstanding
189.03MSharesUpdated Aug 21, 2026Float Shares
91.12MSharesUpdated Aug 21, 2026% Held by Insiders
51.12%vs all stocks
% Held by Institutions
1.92%vs all stocks
Total Cash (MRQ)
613.78MCNY91.27M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.27CNYUpdated Aug 21, 2026Total Debt (MRQ)
334.75MCNY49.78M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2053xCurrent Ratio (MRQ)
4.69xBook Value per Share (MRQ)
8.53CNYUpdated Aug 21, 2026Total Assets
2.20BCNY326.95M · vs all stocks (USD)
Total Current Assets
1.01BCNYFY2025 · Dec 31, 2025Total Liabilities
583.75MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.19BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
337.05MCNYFY2025 · Dec 31, 2025Total Current Liabilities
246.70MCNYFY2025 · Dec 31, 2025Cash
427.47MCNYFY2025 · Dec 31, 2025Cash Equivalents
30.20MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
457.67MCNYFY2025 · Dec 31, 2025Other Short-term Investments
182.06MCNYFY2025 · Dec 31, 2025Accounts Receivable
152.83MCNYFY2025 · Dec 31, 2025Inventory
189.74MCNYFY2025 · Dec 31, 2025Accounts Payable
182.18MCNYFY2025 · Dec 31, 2025Short-term Debt
6.32MCNYFY2025 · Dec 31, 2025Other Current Liabilities
5.14MCNYFY2025 · Dec 31, 2025Long-term Debt
317.75MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
8.10MCNYFY2025 · Dec 31, 2025Common Stock (Book)
189.03MCNYFY2025 · Dec 31, 2025Retained Earnings
444.88MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.61BCNY240.14M · vs all stocks (USD)
Treasury Stock
21.13MCNYFY2025 · Dec 31, 202552-Week Low
9.94CNYUpdated Aug 21, 202652-Week High
22.00CNYUpdated Aug 21, 202652-Week Change
-29.48%vs all stocks
Beta
0.2960xvs all stocks
50-Day MA
11.81CNYUpdated Aug 21, 2026200-Day MA
16.23CNYUpdated Aug 21, 2026Avg 10-Day Volume
9.57MSharesUpdated Aug 21, 2026Avg 30-Day Volume
5.48MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.2900CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.68: safe zoneNotable
Altman Z-Score: 3.68
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Aprilbio Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
X4 Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule